White House officials have high expectations for the next generation of COVID-19 vaccines, a bar that may prove difficult to meet. Shifting market dynamics and a less hospitable research environment are now added to the scientific challenges that sponsors face.
Increasing efficacy likely will not be enough to replace the roster of available shots. Ashish Jha, White House COVID-19 response...







